Pharmaceutical companies Bristol-Myers Squibb

Bayer Company operates several microprocess plants. Clariant GmbH has formed a competence center on microreaction technology in early 2004 to offer the technology in its custom synthesis business. Lonza has also used microreaction technology over years for pharmaceutical customers. The pharmaceutical company Bristol-Myers Squibb, Lucent Technologies, and the Stevens Institute work on a public funded project on hydrogenation reactions [84]. They started with a model reaction, the hydrogenation of o-nitroanisole to o-anisidine, and will move to proprietary reactions. 

Bristol-Myers Squibb Company, Pharmaceutical Research Institute,... 

Anti-Tumor Chemistry, 2CNS Biology, Bristol-Myers Squibb Company, Pharmaceutical Research and Development Division, Wallingford, CT 06492-7660, U.S.A. 

Some chemical companies spend a very high percentage of sales on R D expenditures. Almost all of these companies are pharmaceutical companies, that portion of the industry that is highly competitive technically and requires substantial basic research to remain competitive. These types of companies can spend large percentages of their sales on R D Pfizer, 17% Bristol-Myers Squibb, 9% Eli Lilly, 18%. Most general large U.S. chemical companies spend a smaller portion of their sales on R D Du Pont, 6% Dow, 5% Rohm and Haas, 4% Eastman Chemical, 4%. 

There are five basic sources of pharmaceuticals. By dollar value of products, fermentation is probably the most important, whereas by tonnage, chemical synthesis is dominant. Fermentation is used for antibiotics such as penicillins and tetracyclines. Chemical synthesis provides drugs such as the psychotropics and antihistamines. Animal extracts provide hormones. Biological sources lead to vaccines and serums. Vegetable extracts provide steroids and alkaloids. The top ten pharmaceutical companies in order of revenues are the following Merck, Pfizer, Bristol-Myers Squibb, Johnson ... 

Cheminformatics, Johnson Johnson, Pharmaceutical Research Development, L.L.C., San Diego, California, USA Brett R. Beno Computer Aided Drug Design, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, New Jersey, USA Curt Breneman Department of Chemistry, Rensselaer Polytechnic Institute, Troy, New York, USA... 

Andrew Good Computer Aided Drug Design, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, New Jersey, USA... 

Baldauf, Sarah. Former Pharma Pitchman Beware of New Drugs. Interview with T. Nesi. U.S. News World Report 145, no. 10 (November 3-10, 2008) 64. Tom Nesi, formerly the director of public affairs at Bristol-Myers Squibb, has an insider s view of the sales and marketing tactics used by pharmaceutical companies. Based on his experiences, he warns consumers to avoid taking free sample pills, exercise caution when offered a new medication, and learn about potential side effects. Fie also talks about the history of Vioxx, a drug removed form the market after research showed it caused heart attacks and strokes. 

Bristol-Myers Squibb URL http //www.bms.com E-mail web form Phone (800) 332-2056 345 Park Avenue New York, NY 10154 The company s pharmaceuticals segment makes Plavix and Pravachol for cardiovascular problems, Taxol for cancer treatment, drugs such as Abilify for affective and other psychiatric disorders, Avapro for hypertension, and Reyataz for HIV... 

Brand Name/ Company Ancet (cefazolin)/SmithKline Beecham Pharmaceuticals Cefotan (cefotetan)/Zeneca Pharmaceuticals Rocephin (ceftriaxone)/Roche Pharmaceuticals Maxipime (cefepime)/Bristol-Myers Squibb Company... 

Company Merck Co., Inc. Zeneca Pharmaceuticals Merck Co., Inc. Bristol-Myers Squibb Co. 

Taxol is a registered trademark of Bristol-Myers Squibb Company for an anticancer pharmaceutical preparation containing paclitaxel. 

Kabi Vitrum, Stockholm, Sweden Roche Laboratories Inc., Nutley, New Jersey Astra Zeneca, Wilmington Delaware Bristol-Myers Squibb, Princeton, New Jersey Hospira, Lake Forest, Illinois InvensysAPV, Denmark MicroLuidics, Newton Massachusetts Five Star Technologies, Cleveland, Ohio Abitec Corp, Columbus, Ohio BASF, Mount Olive, New Jersey Sasol North America Inc., Houston, Texas Uniqema North America Inc., Chicago, Illinois Stepan Company, NorthLeld, Illinois Novartis Pharmaceuticals Corporation, East Hanover, New Jersey... 

Rong (Ron) Liu has been in the pharmaceutical industry for 20 years, and is currently leading AustarPharma, a pharmaceutical company based at Edison, New Jersey. The core competence of the company is drug delivery technologies. Before his current role, Ron was employed at Bristol-Myers Squibb (BMS) as a director of global product development for more than 5 years. 

Debra Henn holds a Doctor of Pharmacy degree from the University of the Sciences in Philadelphia, Philadelphia College of Pharmacy. She completed a post-doctoral specialty residency in drug information at Thomas Jefferson University Hospital in Philadelphia and Bristol-Myers Squibb Company, Plainsboro New Jersey. Dr. Henn is currently employed as a Medical Information Manager at AstraZeneca Pharmaceuticals in Wilmington, Delaware. 

A number of the major pharmaceutical companies have used biocatalytic approaches based on esterases and lipases to prepare target drugs or intermediates.107 183 187 Most of these approaches involve resolutions that use a racemic ester or amide as substrate, whereby yields of 50% can only be realized. Examples of resolutions applied to pharmaceutical intermediates such as the paclitaxel (Taxol ) sidechain and J -(+)-BMY-14802, an antipsychotic agent, have been described by the Bristol-Myers Squibb group.107... 

Ramesh N. Patel, Process Research and Development, Bristol-Myers Squibb Company, Pharmaceutical Research Institute, P.O. Box 191, New Brunswick, NJ 08903 patelR BMS.com Elba Pinto da Silva Bon, Instituto de Quimica, Universidade Federal do Rio de Janeiro, CEP 21949-900, Rio de Janeiro, RJ, Brasil elbal996 iq.ufrj. br... 

R D business, explains, the information comes from interviews with 40 to 50 pharmaceutical companies, biotechs, and academic institutions, including Pharmacia Corporation Roche Bristol-Myers Squibb Company Aventis Biogen, Inc. Harvard, and the Massachusetts Institute of Technology. All have a relationship of some sort with Boston Consulting— they might be clients or the alma maters of Boston consultants, or they might have provided advice to Boston at one time. 

Figure 2 Sum of annual R D spending by six large pharmaceutical companies in the United States Pfizer, Merck, Eli Lilly, Bristol-Myers Squibb, American Home Products (renamed Wyeth in 2002), and Schering-Plough. These companies are listed in descending order of the total amount of their profit spent on R D. In terms of R D investment in 2000 as of percentage of sales that year, the order of the companies changes to Eli Lilly (19%), Pfizer (15%), Schering-Plough (14%), American Home Products (13%), Bristol-Myers Squibb (11%), and Merck (6%). On average, these companies spent almost 12% of their 2000 sales on R D. Data from Ref. 8.

There has been and will continue to be iimovative reconstruction of the pharmaceutical industry with, for example, cross-licensing of products and expertise. Sandoz collaborated with Bristol Myers Squibb (BMS) in oncology. Other companies have a more acquisitive outlook. Pfizer bought Warner-Lambert for its cholesterol-lowering Lipitor, and Pharmacia merged with UpJohn-Searle for its COX-2 inhibitor. Pfizer then acquired Pharmacia-UpJohn-Searle to become the world s largest pharmaceutical company. 

---